Related Experiment Video
Updated: Dec 21, 2025
09:38
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.3K
Differences in failure patterns according to the EGFR mutation status after proton beam therapy for early stage
Masaki Nakamura1, Shun-Ichiro Kageyama1, Hibiki Udagawa2
1Division of Radiation Oncology and Particle Therapy, National Cancer Center Hospital East, Chiba, Japan.
Abstract:
We analyzed 135 patients (including 27 EGFR-mutant and 29 EGFR-wild) with T1-3N0M0 non-squamous NSCLC treated by PBT. Considering the 3-year cumulative incidence, the EGFR-mutant group showed a significantly lower infield failure rate (9% vs 27%, p = 0.02) and higher out-of-field failure rate (67% vs 40%, p = 0.02) than the EGFR-wild group.
